Indeed, three other retrospective studies of patients treated with T-VEC also reported lower frequencies of BRAF mutations compared with all melanoma patients: 35.2% (31/88),19 and 22.8% (19/83),18 36.4% (24/66),32 and 22.4% (17/76).16 Here, BRAF is linked to melanoma.